Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$189.85 +2.8%	$194.23	$153.58 ▼ $218.66	$335.83B	0.56	6.16 million shs	12.79 million shs
LLY Eli Lilly and Company	$755.28 +2.8%	$807.49	$677.09 ▼ $972.53	$715.80B	0.48	3.54 million shs	9.15 million shs
MRK Merck & Co., Inc.	$80.28 +5.7%	$85.01	$73.57 ▼ $134.63	$190.76B	0.43	12.22 million shs	21.75 million shs
PFE Pfizer	$23.09 +3.6%	$23.96	$20.92 ▼ $31.54	$131.25B	0.58	40.67 million shs	77.37 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	0.00%	-7.21%	+5.38%	-3.16%	+14.65%
LLY Eli Lilly and Company	0.00%	-10.77%	+0.63%	-15.24%	-3.13%
MRK Merck & Co., Inc.	0.00%	-8.73%	-4.12%	-12.30%	-41.66%
PFE Pfizer	0.00%	-7.90%	+1.79%	-13.86%	-20.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.9135 of 5 stars	3.4	4.0	4.2	3.9	3.4	2.5	1.3
LLY Eli Lilly and Company	4.994 of 5 stars	4.4	5.0	3.3	4.0	3.2	2.5	1.9
MRK Merck & Co., Inc.	4.9963 of 5 stars	3.3	3.0	5.0	3.9	4.1	2.5	3.8
PFE Pfizer	4.9993 of 5 stars	4.3	3.0	4.2	4.3	3.4	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.86	Moderate Buy	$211.41	11.36% Upside
LLY Eli Lilly and Company	2.81	Moderate Buy	$1,002.80	32.77% Upside
MRK Merck & Co., Inc.	2.59	Moderate Buy	$111.13	38.43% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	26.34% Upside

Current Analyst Ratings Breakdown

Latest ABBV, MRK, LLY, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	ABBV AbbVie	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/2/2025	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,100.00 ➝ $1,050.00
5/1/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/1/2025	LLY Eli Lilly and Company	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/1/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/29/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$214.00 ➝ $216.00
4/28/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Reduce	$1,150.00 ➝ $700.00
4/28/2025	ABBV AbbVie	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$204.00 ➝ $205.00
4/28/2025	ABBV AbbVie	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$241.00 ➝ $250.00
4/28/2025	LLY Eli Lilly and Company	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Moderate Sell

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$57.37B	5.85	$14.03 per share	13.53	$1.90 per share	99.92
LLY Eli Lilly and Company	$49.00B	14.61	$12.31 per share	61.34	$15.05 per share	50.18
MRK Merck & Co., Inc.	$63.92B	3.15	$2.79 per share	28.82	$14.85 per share	5.41
PFE Pfizer	$62.46B	2.10	$3.62 per share	6.38	$15.81 per share	1.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	79.10	13.58	1.62	7.59%	296.28%	12.65%	7/24/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$12.29	64.50	24.27	1.40	23.51%	85.24%	16.19%	N/A
MRK Merck & Co., Inc.	$17.12B	$6.87	11.93	8.11	0.77	26.67%	45.35%	17.36%	7/29/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	16.37	7.62	0.64	12.62%	19.47%	8.09%	7/29/2025 (Estimated)

Latest ABBV, MRK, LLY, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.46%	+6.04%	279.15%	53 Years
LLY Eli Lilly and Company	$6.00	0.79%	+15.21%	48.82%	11 Years
MRK Merck & Co., Inc.	$3.24	4.04%	+5.73%	47.16%	14 Years
PFE Pfizer	$1.72	7.45%	+2.50%	124.64%	16 Years

Latest ABBV, MRK, LLY, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025
2/13/2025	ABBV AbbVie	quarterly	$1.64	3.4%	4/15/2025	4/15/2025	5/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	17.94	0.66	0.55
LLY Eli Lilly and Company	2.00	1.15	0.97
MRK Merck & Co., Inc.	0.79	1.36	1.15
PFE Pfizer	0.63	1.00	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
LLY Eli Lilly and Company	0.13%
MRK Merck & Co., Inc.	0.13%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	50,000	1.77 billion	1.76 billion	Optionable
LLY Eli Lilly and Company	39,000	947.74 million	948.08 million	Optionable
MRK Merck & Co., Inc.	69,000	2.51 billion	2.53 billion	Optionable
PFE Pfizer	83,000	5.69 billion	5.66 billion	Optionable

ABBV, MRK, LLY, and PFE Headlines

Recent News About These Companies

Trump’s “Most Favored Nation” Drug Pricing Order Faces Legal and Industry Pushback

May 12 at 3:58 PM | quiverquant.com

Pfizer Inc (PFE) Shares Up 3.64% on May 12

May 12 at 1:20 PM | gurufocus.com

Pfizer partner RemeGen says HER2 ADC prolongs life in newly diagnosed bladder cancer

May 12 at 12:49 PM | fiercepharma.com

Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs

May 12 at 10:41 AM | zacks.com

25,066 Shares in Pfizer Inc. (NYSE:PFE) Purchased by Investor s Fiduciary Advisor Network LLC

May 12 at 8:30 AM | marketbeat.com

Apple, Amazon and Chevron rise premarket; Pfizer, Eli Lilly fall

May 12 at 8:02 AM | investing.com

Kahn Brothers Group Inc. Sells 235,935 Shares of Pfizer Inc. (NYSE:PFE)

May 12 at 7:45 AM | marketbeat.com

Humankind Investments LLC Acquires 15,319 Shares of Pfizer Inc. (NYSE:PFE)

May 12 at 7:27 AM | marketbeat.com

Pfizer, Eli Lilly, Other Pharma Stocks Fall as Trump Targets Lower Drug Prices

May 12 at 7:10 AM | barrons.com

Pfizer Inc. (NYSE:PFE) Shares Acquired by Focus Partners Wealth

May 12 at 6:54 AM | marketbeat.com

Wondering if Pfizer's 7.6% Dividend Yield Is Sustainable? Here's What You Need to Know.

May 12 at 6:04 AM | fool.com

Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket

May 12 at 5:19 AM | benzinga.com

Game Creek Capital LP Sells 35,625 Shares of Pfizer Inc. (NYSE:PFE)

May 11 at 7:07 AM | marketbeat.com

Freedom Together Foundation Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)

May 11 at 6:16 AM | marketbeat.com

Fiduciary Trust Co Cuts Stake in Pfizer Inc. (NYSE:PFE)

May 11 at 5:51 AM | marketbeat.com

First Manhattan CO. LLC. Reduces Holdings in Pfizer Inc. (NYSE:PFE)

May 11 at 5:44 AM | marketbeat.com

Fred Alger Management LLC Purchases 13,743 Shares of Pfizer Inc. (NYSE:PFE)

May 11 at 5:43 AM | marketbeat.com

Rep. Jefferson Shreve Sells Off Shares of Pfizer Inc. (NYSE:PFE)

May 11 at 5:02 AM | marketbeat.com

Brokerages Set Pfizer Inc. (NYSE:PFE) PT at $29.17

May 11 at 2:05 AM | americanbankingnews.com

Pfizer (NYSE:PFE) Shares Down 0.1% - Here's What Happened

May 10 at 2:13 PM | marketbeat.com

Elyxium Wealth LLC Trims Position in Pfizer Inc. (NYSE:PFE)

May 10 at 8:05 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
By Chris Markoch | April 16, 2025
View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
Fundamentally Sound, These 5 Stocks Sold Off Anyway
By Thomas Hughes | April 23, 2025
View Fundamentally Sound, These 5 Stocks Sold Off Anyway
3 High-Yield Dividend Stocks That Could Rally Near 52-Week Lows
By Chris Markoch | May 1, 2025
View 3 High-Yield Dividend Stocks That Could Rally Near 52-Week Lows
Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged
By Sam Quirke | April 30, 2025
View Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged
3 High-Yield Dividend Stocks on Sale After Wild Market Swing
By Nathan Reiff | April 14, 2025
View 3 High-Yield Dividend Stocks on Sale After Wild Market Swing

ABBV, MRK, LLY, and PFE Company Descriptions

AbbVie NYSE:ABBV

$189.84 +5.25 (+2.84%)

Closing price 03:59 PM Eastern

Extended Trading

$190.49 +0.65 (+0.34%)

As of 07:43 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Eli Lilly and Company NYSE:LLY

$755.28 +20.71 (+2.82%)

Closing price 03:59 PM Eastern

Extended Trading

$758.52 +3.25 (+0.43%)

As of 08:00 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$80.28 +4.31 (+5.67%)

Closing price 03:59 PM Eastern

Extended Trading

$80.38 +0.10 (+0.12%)

As of 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$23.08 +0.81 (+3.61%)

Closing price 03:59 PM Eastern

Extended Trading

$22.93 -0.16 (-0.67%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time